Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amibegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 12/20 | 0.89 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amibegron SCHEMBL9316758 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3897918 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3897916 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL29380172 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL2335205 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL9317343 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3898164 | 0.99 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3824162 | 0.99 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL9006793 | 0.99 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL8765764 | 0.99 | ADRB3 (0.91) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294881-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING alpha2delta SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | EDUSA PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-1901775-B1 | KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION | JERINI AG (DE) | 2011-08-24 | — | — | EP | disclosed |
| EP-1382333-B1 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | ASTELLAS PHARMA INC (JP) | 2009-02-25 | — | — | EP | disclosed |
| US-20080275080-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit channel modulators with smooth muscle modulators | DYNOGEN PHARMACUETICALS, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080221039-A1 | Kinin Antagonists For Treating Bladder Dysfunction | JERINI AG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080085916-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| EP-1539181-B1 | METHOD OF TREATING LOWER URINARY TRACT DISORDERS | DYNOGEN PHARMACEUTICALS INC (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1795196-A2 | Method of treating lower urinary tract disorders | Dynogen Pharmaceuticals, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| US-7217706-B2 | Propanolamine derivatives | ASTELLAS PHARMA INC. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MYRIAD GENETICS, INCORPORATED (US) | 2007-01-18 | — | — | US | disclosed |
| WO-2004089288-A2 | METHOD OF TREATING LOWER URINARY TRACT DISORDERS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040198822-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators | DYNOGEN PHARMACUETICALS, INC. (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1382333-A2 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-21 | — | — | EP | disclosed |
| EP-0940387-B1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | MITSUBISHI PHARMA CORP (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-20020120148-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| EP-0801059-B1 | INDOLE DERIVATIVE | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-06-27 | — | — | EP | disclosed |
| US-6069176-A | PHENYLETHANOLAMINE COMPOUNDS WITH A BETA-3 ADRENERGIC RECEPTOR STIMULATING EFFECT, USE AS A THERAPY FOR URINARY INCONTINENCE | MITSUBISHI-TOKYO PHARMACEUTICALS, INC. (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0940387-A1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | TOKYO TANABE COMPANY LIMITED (JP) | 1999-09-08 | — | — | EP | disclosed |
| US-5817689-A | ADRENERGIC RECEPTOR-STIMULATING AGENT, OBESITY, DIABETES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0801059-A1 | INDOLE DERIVATIVE | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1997-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MME, AVPR1B, AVPR2 | ADRB3 41/4885ADRB1 35/4885 |
| US-20040198822-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators | GABRB2, GABRD, GABRB3 | ADRB3 71/4885ADRB1 60/4885 |
| US-20080221039-A1 | Kinin Antagonists For Treating Bladder Dysfunction | BDKRB2, BDKRB1, F2R | ADRB3 198/4885ADRB1 143/4885 |
| US-20080085916-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | GABRB2, GABRB3, GABRB1 | ADRB3 40/4885ADRB1 32/4885 |
| US-20080275080-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit channel modulators with smooth muscle modulators | GABRB2, GABRB3, GABRB1 | ADRB3 31/4885ADRB1 25/4885 |
| US-20020120148-A1 | Propanolamine derivatives | AMY2A, PNMT, PNLIP | ADRB3 12/4885ADRB1 6/4885 |
| US-20110294881-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING alpha2delta SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | GABRB2, GABRB3, GABRB1 | ADRB3 40/4885ADRB1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.